Earnings Release and Estimates - Thermo Fisher Scientific Inc (TMO) is scheduled to release its Q4 2024 results on Jan 30 before market open [1] - The Zacks Consensus Estimate for Q4 revenues is $11.25 billion, indicating 3.3% YoY growth [3] - The consensus estimate for Q4 earnings is $5.92 per share, suggesting 4.4% YoY growth [3] - Earnings estimates have remained unchanged at $5.92 per share over the past 30 days [4] Segment Performance Expectations Analytical Instruments - Expected to generate strong Q4 sales driven by newly launched cutting-edge technologies [5] - Introduced Thermo Scientific Iliad (Scanning) Transmission Electron Microscope in Q4 [5] - R&D 100 Awards honored Thermo Scientific Orbitrap Astral Mass spectrometer in Q3 [6] - Model projects $2.19 billion in Q4 revenues, representing 7.5% YoY growth [6] Life-Science Solutions - Likely experienced sales decline due to runoff of pandemic-related revenues [7] - Launched Applied Biosystems MagMAX Sequential DNA/RNA kit and Invitrogen Vivofectamine Delivery Solutions in Q3 [8] - Bioproduction business likely grew due to strong adoption in pharma and biotech segment [9] - Model expects $2.65 billion in Q4 revenues, indicating 7.5% YoY improvement [10] Specialty Diagnostics - Expected to gain positive contributions from transplant diagnostics and immunodiagnostics businesses [11] - Received FDA approval for Ion Torrent Oncomine Dx Target Test as companion diagnostic in Q4 [11] - Partnered with National Cancer Institute on myeloMATCH precision medicine trial in Q3 [12] - Model projects $1.13 billion in Q4 revenues, suggesting 2% YoY growth [13] Laboratory Products and Services - Revenues expected to increase due to research and safety market channel [14] - Introduced Thermo Scientific iCAP MX Series ICP-MS in Q4 [14] - Opened first electron microscopy demo center (NanoPort) in Taiwan and expanded global laboratory services with new bioanalytical lab in Sweden during Q3 [15] - Model expects $5.72 billion in Q4 revenues, flat YoY [16] Quantitative Model Predictions - Thermo Fisher has an Earnings ESP of +0.65% [17] - The company currently carries a Zacks Rank 4 [17] Other Medical Stocks to Watch - Argenx (ARGX) has Earnings ESP of +44.82% and Zacks Rank 2, expected to release Q4 2024 results on March 6 [18] - Arcutis Biotherapeutics (ARQT) has Earnings ESP of +7.97% and Zacks Rank 2, expected to release Q4 2024 results on Feb 25 [19] - Axogen (AXGN) has Earnings ESP of +36.36% and Zacks Rank 2, likely to release Q4 2024 results on March 4 [20]

Company Performance - Thermo Fisher Scientific (NYSE: TMO) stock has shown little growth for its shareholders since August 2021 [1] - The company is expected to potentially reverse this trend and begin seeing growth again by 2025 [1] Analyst Perspective - The analyst specializes in financials, consumer, and technology industries with over seven years of experience [1] - The analyst prioritizes deep research into business model trends to understand future company perspectives rather than focusing on short-term market trends or stock prices [1] - This research approach is considered valuable for identifying long-term growth investment opportunities while avoiding risky financial instruments [1] Disclosure - The analyst has no current stock, option, or derivative positions in the mentioned companies but may initiate a long position in TMO within the next 72 hours [2] - The article represents the analyst's personal opinions and is not influenced by compensation or business relationships with the mentioned companies [2]

Key Takeaways Company and Industry Overview 1. **Company**: Thermo Fisher Scientific Inc. (NYSE:TMO) 2. **Event**: 43rd Annual J.P. Morgan Healthcare Conference Call 3. **Date**: January 14, 2025 4. **Time**: 11:15 AM ET 5. **Participants**: Marc Casper - CEO, Sandy Pound - Chief Communications Officer, Raf Tejada - Vice President of Investor Relations, Rachel Vatnsdal - JPMorgan Performance and Future Outlook 6. **2024 Performance**: Strong differentiated performance delivered in 2024 [5] 7. **Upcoming Results**: Results to be reported in a couple of weeks [5] 8. **Industry Position**: Thermo Fisher is an industry leader with leading businesses enabling customer success [5] 9. **Market Share**: Gaining market share in the industry [5] 10. **End Markets**: Serving attractive end markets [5] 11. **Long-term Growth Drivers**: Sound and create a bright future for the industry and the company [5] Additional Notes 12. **Non-GAAP Financials**: Safe harbor statement and non-GAAP financials available on the company's website [4]

Thermo Fisher's Challenges - Thermo Fisher has been experiencing a continuous decline in COVID testing-related demand, particularly impacting the Life Science Solutions and diagnostics businesses [2] - Selling, general and administrative expenses increased by 10.2% year-over-year in Q3 2024 [3] - The company faces intense competition from manufacturers and third-party distributors, requiring ongoing R&D to meet changing technology and customer demands [3] Growth Drivers for Thermo Fisher - The biosciences and bioproduction businesses have expanded capacity to meet global vaccine manufacturing needs [4] - Strong growth in electron microscopy business and research/safety market channels within academic/government and industrial/applied end markets [4] - Recent $3.1 billion acquisition of Olink Holdings enhances capabilities in the high-growth proteomics market, expected to deliver $125 million in adjusted operating income synergies by year five [5] - Expansion of bioproduction purification resin capacity in China and Singapore to support mRNA manufacturing and meet global biopharma demand [6] - Enhancement of regional capabilities in South Korea through customer-focused innovation centers for semiconductor and biopharma industries [6] Industry Comparison - Thermo Fisher's shares gained 2.1% in the past year, underperforming the industry's 5.4% growth [7] - Abbott (ABT) shares declined 0.7% with consistent 2024 EPS estimates of $4.67 and an average earnings surprise of 1.64% [10] - Haemonetics (HAE) shares dropped 4.4% against industry growth of 7.8%, with fiscal 2025 EPS estimates remaining at $4.59 and an average earnings surprise of 2.82% [11] - Phibro Animal Health (PAHC) shares surged 77.6% compared to industry growth of 7.8%, with fiscal 2025 EPS estimates increasing 1.9% to $1.62 and an average earnings surprise of 25.47% [12] Macroeconomic and Geopolitical Factors - International markets contribute significantly to revenues, but currency fluctuations could adversely impact reported revenues and profitability [13] - Geopolitical pressures, including Russia-Ukraine war and China-Taiwan tensions, have increased cybersecurity risks and disrupted global supply chains and labor markets [14] - Volatile financial markets and price/availability fluctuations of goods and services are putting pressure on profitability [14]

Thermo Fisher's (TMO) Bioproduction business prospects look promising. Strategic buyouts and partnerships are likely to drive the company’s growth. Yet, macroeconomic issues and currency fluctuations dampen growth. The stock carries a Zacks Rank #3 (Hold).Factors Driving TMO's SharesThermo Fisher’s business strategy primarily includes expansion through strategic acquisition of technologies and businesses that augment the company’s existing products and services. As a result of these acquisitions, Thermo Fis ...

I have already written two articles about Thermo Fisher (NYSE: TMO ), one of my favorite companies in the healthcare sector. I recommend you take a look at them if you want to fully understand my perspective on theI am an investor who relies on the fundamental aspects of companies. I enjoy being the owner of the world's best businesses with strong long-term projections. To achieve this, I conduct thorough research on the companies I invest in, placing significant importance on the sector, competitive advant ...

With talk about the sell-off of Thermo Fisher Scientific’s (TMO) shares by institutional investors and company insiders, market sentiment toward the company seems bearish. The stock has lost 12.7% in the past three months, and despite the company’s recent completion of a $1 billion share repurchase and several other positive developments, the recuperation might take a little time.In the past three months, the stock has underperformed the broader industry’s 2.9% drop and the medical sector’s 9.8% decline. Th ...

Thermo Fisher Scientific (TMO) has introduced the Gibco CTS Detachable Dynabeads CD4 and CTS Detachable Dynabeads CD8 (CTS Detachable Dynabeads). These latest products expand on the company’s CTS Detachable Dynabeads platform, which represents a new generation of cell therapy isolation and/or activation products that prioritize cell quality while creating greater workflow control.At the core, these products can help customers maximize the potential of their therapies to save more lives. Per TMO, the number ...

I think that Thermo Fisher (NYSE: TMO ) is a good investment opportunity. The company has grown 174% between 2017 and 2024 Q3 TTM. The strategy of acquiring different companies has been the main factor for such growth. In addition, the LifeDaniel Mellado is an economist from Carabobo University with a Master's Degree in Statistics from Simon Bolivar University, both obtained in Venezuela.Daniel worked analyzing the agricultural commodity market and the financial investment portfolio for an agribusiness grou ...

Investment Rating - The report initiates coverage on Thermo Fisher with a "Buy" rating and sets a target price of $670 [1][5][33]. Core Insights - Thermo Fisher is positioned as a global leader in the life sciences sector, benefiting from industry improvement trends and a comprehensive product and service portfolio [1][2]. - The company is expected to experience revenue growth of +0.4% in 2024, +5.6% in 2025, and +8.3% in 2026, with Non-GAAP net profit growth of -1.0%, +5.7%, and +10.4% respectively [1][2]. - The report highlights the anticipated recovery in biotech financing, driven by the Federal Reserve's shift to a rate-cutting environment, which is expected to boost customer demand [1][2]. Summary by Sections Company Overview - Thermo Fisher has the largest business scale and service range in the industry, providing integrated services from drug discovery to commercial production [1][2]. - The company’s bioproduction services offer a competitive edge in securing customer orders, while its CDMO business addresses clinical trial supply challenges [1][2]. Financial Strength - Thermo Fisher is an active consolidator in the life sciences sector, with management planning to allocate 60%-75% of capital for mergers and acquisitions [1][2]. - The company has consistently generated robust free cash flow, providing a solid financial foundation for future expansions [1][2]. Market Trends - The global life sciences market is projected to grow due to increasing demand for pharmaceuticals, drug production costs, and R&D expenditures [1][2]. - The report notes that downstream customers are expected to complete inventory destocking by 2024, which will normalize order patterns [1][2]. Financial Projections - The report provides detailed financial forecasts, including projected sales revenue of $43,033 million in 2024, with a growth trajectory leading to $49,234 million by 2026 [2][28]. - Adjusted net profit is forecasted to be $8,278 million in 2024, increasing to $9,662 million by 2026 [2][28].